报价延迟最少15分钟:2026/01/07 17:07 EST
盘后时段
|
||||
|
3.61 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.61
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-22.90/-6.35
|
|
企业价值
36.22M
|
| 资产负债 |
|
每股账面净值
-2.44
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
1.53M
|
|
每股收益
0.80
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS. |
